Eslicarbazepine acetate add‐on for drug‐resistant partial epilepsy
References
Additional references
Almeida L, Soares‐da‐Silva P. Eslicarbazepine acetate (BIA 2‐093). Neurotherapeutics 2007;4(1):88‐96.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration2009; Vol. Available from www.cochrane‐handbook.org.
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org.
McCormack PL, Robinson DM. Eslicarbazepine acetate. CNS Drugs 2009;23(1):71‐9.
McCullagh P, Nelder JA. Generalized linear models. 2nd Edition. London: Chapman and Hall, 1989.
Mestre T, Ferreira J. Eslicarbazepine acetate: a new option for the treatment of focal epilepsy. Expert Opinion on Investigational Drugs 2009;18(2):221‐9.
Sander JW. The epidemiology of epilepsy revisited. Current Opinion in Neurology 2003;16(2):165‐70.
Schuele SU, Luders HO. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurology 2008;7(6):514‐24.
Walker MC, Sander JW. Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Neurology 1997;49(2):333‐7.
